VivoSeq
Oncology

Pancreatic Cancer Metastatic

7

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Pancreatic Cancer Metastatic is an early-stage landscape with 7 programs across 3 companies. The most active players are Bristol-Myers Squibb, Johnson & Johnson, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc..

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

0/100

Attrition Rate

100/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

5 of 7 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody229%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

1

clinical trials

Terminated1 · 100%

Clinical Trials

Trial Activity

An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab (AGEN1811) + Balsilimab (AGEN2034) + Chloroquine + Celecoxib in Patients With Previously Untreated Metastatic Pancreatic Cancer
Terminated·HHonorHealth Research Institute·Phase 1·NCT06076837·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)